Navigation Links
CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
Date:8/3/2010

GREENWOOD VILLAGE, Colo., Aug. 3 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), discovered an error in the title of its press release on July 27, and provides the corrected title to that release above. As reflected in the body of the press release, Ampio has completed the final negotiations with DMI BioSciences, Inc. concerning the pending acquisition of DMI BioSciences. Ampio will file a Form 8-K with the SEC announcing the definitive agreement upon its execution.  

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The product pipeline includes new uses for previously approved drugs and new molecular entities ("NMEs"). By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near-term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs.

About DMI BioSciences, Inc.

DMI BioSciences, Inc. was founded by Dr. David Bar-Or in 1990 to develop innovative diagnostic tests and drugs for the medical device and biopharmaceutical industry. 

Safe Harbor Statement

Certain of the above statements contained in this press release are forward-looking statement
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
2. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
3. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
4. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
5. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
6. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
9. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Cambridge Healthtech Institute will host its fifth annual ... Renaissance Waterfront Hotel in Boston, MA. The ten ... the current strategies and innovations for optimizing bioprocesses while ... the field will reveal how their work has resulted ... and efficiency. , “In this age of rapid innovation, ...
(Date:5/16/2013)... DIEGO , May 16, 2013  The registration ... of Bioscience Financial Officers (ABFO) 2013 National Conference, the ... be held May 28-31 at the Hilton San Diego ... touches on this year,s conference and want to make ... to attend," said Brandi Roberts , ...
(Date:5/16/2013)... On average, developing a new drug takes ... Despite this investment, less than 10% of drugs make ... clinical trial design optimally structured to balance time, cost ... Frederic Sax, Global Head of the Center for Drug ... information and technology in upfront clinical trial planning and ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – ... Cells: Current and Future Opportunities (13-004) , With ... the primary cells market continues to increase. In this ... most often, how satisfied scientists are with commercially available ... growth rate. ,  , Additionally, terminally differentiated cells ...
Breaking Biology Technology:The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 2Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 3Registration Extended Until May 22 for Association of Bioscience Financial Officers (ABFO) 2013 National Conference -- San Diego 4Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... 24 Favrille, Inc. (OTC,Bulletin Board: FVRL) announced today ... a reverse merger whereby Favrille would acquire,all of the ... a stock for stock merger that would result in ... transaction is,consummated on the terms set forth in the ...
... a 100% organic toxic mold remedy for mold remediation professionals and ... technology used effectively in the aftermath of the flooding in Katrina. ... ... 2008 -- Organic Environmental Technology ( http://www.organicet.com ) announced today the ...
... just five years after Jim Rider, the first American patient to ... American patient milestone. , ... Bremen, Germany (PRWEB) October ... getting worse, and the knowledge that many treatments are just not ...
Cached Biology Technology:Favrille Announces Execution of Non-binding Term Sheet for a Merger Transaction 2Katrina Proven Certified Organic Toxic Mold Remedy Now Available for Mold Remediation Professionals and Homeowners 2Katrina Proven Certified Organic Toxic Mold Remedy Now Available for Mold Remediation Professionals and Homeowners 3Katrina Proven Certified Organic Toxic Mold Remedy Now Available for Mold Remediation Professionals and Homeowners 4Stenum Hospital Does its 600th American Disc Replacement Surgery 2
(Date:5/16/2013)... living closer to a fast food restaurant had a ... further away from fast food, according to researchers at ... this association was particularly strong among those with a ... in the American Journal of Public Health ... fast food restaurant, and among lower-income African-Americans, the density, ...
(Date:5/16/2013)... scientists have shown a gene involved in neurodegenerative disease ... of the circadian clock. , In a study ... gene, called Ataxin-2, keeps the clock responsible for sleeping ... the rhythm of the fruit fly,s sleep-wake cycle is ... for the fly. , The discovery is particularly ...
(Date:5/16/2013)... endothelium, the cellular layer lining the body,s blood ... hundred nanometers in thickness, this super-tenuous structure routinely ... compression to create a unique and highly dynamic ... tissues from the body,s circulatory system. , It,s ... must be physically breached to enable immune ...
Breaking Biology News(10 mins):Body mass index of low income African-Americans linked to proximity of fast food restaurants 2Body mass index of low income African-Americans linked to proximity of fast food restaurants 3Gene involved in neurodegeneration keeps clock running 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... may link viruses that have been considered harmless to ... that we propose is correct, protecting the body against ... may decrease the frequency of cancers and prevent their ... to this model, cells can be made cancerous by ...
... Dutch researcher Harm Veling has demonstrated that our brains fend ... disrupting external influences. If we are tired, we can no ... brain selects incoming information to remember useful things. Distracting information ... of tiredness, this system no longer seems to work. ...
... A Johns Hopkins team has stopped in its tracks ... and inactivating an enzyme, telomerase, thereby shortening the ends ... critically short, the cell commits suicide as a means ... Daniel Nathans chair of molecular biology and genetics at ...
Cached Biology News:Brain fends off distractions 2Short chromosomes put cancer cells in forced rest 2
UV-NIR light source for USB2000, HR4000, HR2000+...
Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
Mouse TrkC Affinity Purified Polyclonal Ab...
Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
Biology Products: